# Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis

> **NCT00727194** · PHASE2 · TERMINATED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 14 (actual)

## Conditions studied

- Myasthenia Gravis

## Interventions

- **DRUG:** eculizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00727194
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2011-03
- **Final completion:** 2011-07
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2019-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00727194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00727194, "Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00727194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*